Showing results (1031-1040 of 1,165) with videos related to
Sort By:
Pageof 117
Journal of Proteome Research|November 28, 2018
200+ Protein Concentrations in Healthy Human Blood Plasma: Targeted Quantitative SRM SIS Screening of Chromosomes 18, 13, Y, and the Mitochondrial Chromosome Encoded ProteomeArthur T Kopylov, Elena A Ponomarenko, Ekaterina V Ilgisonis, et al.Journal of Molecular Recognition : JMR|January 6, 2007
Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction toolsJason A Greenbaum, Pernille Haste Andersen, Martin Blythe, et al.BMC Cancer|April 18, 2015
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancerAnastasia S Proskurina, Tatiana S Gvozdeva, Ekaterina A Alyamkina, et al.Vavilovskii Zhurnal Genetiki I Selektsii|January 12, 2024
RatDEGdb: a knowledge base of differentially expressed genes in the rat as a model object in biomedical researchI V Chadaeva, S V Filonov, K A Zolotareva, et al.Journal of Proteome Research|October 11, 2019
Challenges of the Human Proteome Project: 10-Year Experience of the Russian ConsortiumAlexander I Archakov, Alexander L Aseev, Victor A Bykov, et al.NPJ Breast Cancer|June 17, 2026
Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancerLaia Monserrat, Judith García-García, Cristina Molina, et al.BMC Cancer|August 20, 2016
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of PanagenAnastasia S Proskurina, Tatiana S Gvozdeva, Ekaterina A Potter, et al.Gastroenterology|April 13, 2005
Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survivalTimothy R Morgan, David G Weiss, Bernard Nemchausky, et al.Kardiologiia|December 13, 2023
Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based on Real-World Data from Electronic Medical Records "Intellect 3 Study"K S Benimetskaya, S I Provatorov, M V Ezhov, et al.The Lancet. Oncology|November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 studyShukui Qin, Shanzhi Gu, Stephen L Chan, et al.Pageof 117